Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADI-PEG 20 in advanced hepatocellular carcinoma
NCT01287585Phase 3Completed
- Sponsor
- Polaris Group
- Start
- Jul 2011
- Primary completion
- Jul 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
A Phase 3 trial of Pegargiminase in hepatocellular carcinoma (HCC), sponsored by Polaris Group. Started Jul 2011; status: completed.
02
Drugs
Pegargiminase
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01287585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01287585.